Bate Sebastian, Stokes Victoria, Greenlee Hannah, Goh Kwee Yen, Whiting Graham, Kitchen Gareth, Martin Glen P, Parker Alexander J, Wilson Anthony
Research & Innovation, Manchester Academic Health Science Centre, Manchester University NHS Foundation Trust, Manchester, United Kingdom.
Centre for Biostatistics, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom.
Crit Care Explor. 2024 Mar 27;6(4):e1067. doi: 10.1097/CCE.0000000000001067. eCollection 2024 Apr.
To externally validate clinical prediction models that aim to predict progression to invasive ventilation or death on the ICU in patients admitted with confirmed COVID-19 pneumonitis.
Single-center retrospective external validation study.
Routinely collected healthcare data in the ICU electronic patient record. Curated data recorded for each ICU admission for the purposes of the U.K. Intensive Care National Audit and Research Centre (ICNARC).
The ICU at Manchester Royal Infirmary, Manchester, United Kingdom.
Three hundred forty-nine patients admitted to ICU with confirmed COVID-19 Pneumonitis, older than 18 years, from March 1, 2020, to February 28, 2022. Three hundred two met the inclusion criteria for at least one model. Fifty-five of the 349 patients were admitted before the widespread adoption of dexamethasone for the treatment of severe COVID-19 (pre-dexamethasone patients).
Ability to be externally validated, discriminate, and calibrate.
Articles meeting the inclusion criteria were identified, and those that gave sufficient details on predictors used and methods to generate predictions were tested in our cohort of patients, which matched the original publications' inclusion/exclusion criteria and endpoint.
Thirteen clinical prediction articles were identified. There was insufficient information available to validate models in five of the articles; a further three contained predictors that were not routinely measured in our ICU cohort and were not validated; three had performance that was substantially lower than previously published (range -statistic = 0.483-0.605 in pre-dexamethasone patients and = 0.494-0.564 among all patients). One model retained its discriminative ability in our cohort compared with previously published results ( = 0.672 and 0.686), and one retained performance among pre-dexamethasone patients but was poor in all patients ( = 0.793 and 0.596). One model could be calibrated but with poor performance.
Our findings, albeit from a single center, suggest that the published performance of COVID-19 prediction models may not be replicated when translated to other institutions. In light of this, we would encourage bedside intensivists to reflect on the role of clinical prediction models in their own clinical decision-making.
目的 背景:对外验证旨在预测确诊新冠肺炎肺炎患者在重症监护病房(ICU)进展为有创通气或死亡的临床预测模型。
单中心回顾性外部验证研究。
ICU电子病历中常规收集的医疗保健数据。为英国重症监护国家审计与研究中心(ICNARC)的目的,为每次ICU入院记录的整理后数据。
英国曼彻斯特皇家医院的ICU。
2020年3月1日至2022年2月28日期间,349例确诊新冠肺炎肺炎且年龄大于18岁的患者入住ICU。302例符合至少一种模型的纳入标准。349例患者中有55例在广泛采用地塞米松治疗重症新冠肺炎之前入院(地塞米松治疗前患者)。
进行外部验证、区分和校准的能力。
识别符合纳入标准的文章,并在我们符合原始出版物纳入/排除标准和终点的患者队列中测试那些提供了所用预测因素和生成预测方法足够详细信息的文章。
识别出13篇临床预测文章。5篇文章中没有足够信息来验证模型;另外3篇包含我们ICU队列中未常规测量且未经验证的预测因素;3篇的性能显著低于先前发表的结果(地塞米松治疗前患者中范围-统计量=0.483-0.605,所有患者中=0.494-0.564)。与先前发表的结果相比,一个模型在我们的队列中保留了其区分能力(=0.672和0.686),一个在接受地塞米松治疗前的患者中保留了性能,但在所有患者中表现不佳(=0.793和0.596)。一个模型可以进行校准,但性能较差。
我们的研究结果,尽管来自单一中心,表明新冠肺炎预测模型公布的性能在应用于其他机构时可能无法复制。鉴于此,我们鼓励床边重症监护医生反思临床预测模型在他们自己临床决策中的作用。